Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Aguirre

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Annals of Vascular Surgery|October 17, 2021
Early ABI Testing May Decrease Risk of Amputation for Patients With Lower Extremity UlcersAngela Aguirre, Kritika Sharma, Aman Arora, et al.
Journal of Visualized Experiments : Jove|September 7, 2023
Realistic Membrane Modeling using Complex Lipid Mixtures in Simulation StudiesOluwatoyin Campbell, Van Le, Angela Aguirre, et al.
NPJ Breast Cancer|February 10, 2026
Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxaneMarcin Kubeczko, Sandra Cobo, Rodrigo Sanchez-Bayona, et al.
NPJ Breast Cancer|April 25, 2025
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabRodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Annals of Vascular Surgery|October 17, 2021
Early ABI Testing May Decrease Risk of Amputation for Patients With Lower Extremity UlcersAngela Aguirre, Kritika Sharma, Aman Arora, et al.
Journal of Visualized Experiments : Jove|September 7, 2023
Realistic Membrane Modeling using Complex Lipid Mixtures in Simulation StudiesOluwatoyin Campbell, Van Le, Angela Aguirre, et al.
NPJ Breast Cancer|February 10, 2026
Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxaneMarcin Kubeczko, Sandra Cobo, Rodrigo Sanchez-Bayona, et al.
NPJ Breast Cancer|April 25, 2025
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabRodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, et al.
Pageof 1